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3Abstract
Neuromuscular junctions are synapses that transmit impulses from motor neurons to 
skeletal muscle fibers leading to muscle contraction. Study of hereditary disorders of 
neuromuscular transmission, termed congenital myasthenic syndromes (CMS), has 
helped elucidate fundamental processes influencing development and function of the 
nerve-muscle synapse. Using genetic linkage, we find 18 different biallelic mutations 
in the gene encoding glutamine-fructose-6-phosphate transaminase 1 (GFPT1) in 13 
unrelated families with an autosomal recessive CMS. Consistent with these data, 
downregulation of the GFPT1 orthologue gfpt1 in zebrafish embryos altered muscle 
fiber morphology and impaired neuromuscular junction development. GFPT1 is the 
key enzyme of the hexosamine pathway yielding the amino sugar UDP-N-
acetylglucosamine, an essential substrate for protein glycosylation. Our findings 
provide new impetus to study the glycobiology of NMJ and synapses in general. 
4Introduction 
Efficient signal transmission from the motor neuron to a skeletal muscle fiber at the 
neuromuscular junction (NMJ) is a prerequisite for muscle contraction 1. When an 
action potential reaches the presynaptic button, the neurotransmitter acetylcholine 
(ACh) is released into the synaptic cleft. Binding of ACh to nicotinic acetylcholine 
receptors (AChR) at the motor end plate of the muscle fiber induces opening of the 
cation selective ion channels leading to depolarisation of the muscle fiber, the 
release of calcium ions from the sarcoplasmic reticulum, and ultimately muscle 
contraction. A number of different neurological conditions can result from impaired 
neuromuscular transmission varying from poisoning with botulinum and snake venom 
toxins, through the autoimmune mediated NMJ disorders such as myasthenia gravis 
and the Lambert-Eaton myasthenic syndrome, to the hereditary congenital 
myasthenic syndromes (CMS, for a discussion of genetic heterogeneity of CMS, see 
[MIM 608931]) 2,3. These conditions may lead to generalized paralysis and 
respiratory failure and if untreated can be life-threatening. The neuromuscular 
junction is probably the most studied synapse but many aspects of its formation, 
maturation, stabilization, and functional efficacy remain incompletely understood 4. 
During the last two decades, research into the molecular causes of CMS has led to the 
identification of mutations in several genes and has greatly influenced established or 
inferred concepts of NMJ pathophysiology 3. Here we used positional cloning to 
determine the underlying defect in a rare autosomal recessive CMS that is 
characterized by a limb-girdle pattern of muscle weakness combined with the presence 
of tubular aggregates on muscle biopsies (Myasthenia, limb-girdle, with tubular 
aggregates [MIM 610542]) 5,6. Individuals with this condition have a recognizable 
5pattern of weakness of shoulder and pelvic girdle muscles (Figure 1), sparing of ocular 
or facial muscles, neurophysiologic signs of NMJ dysfunction (decrement of the muscle 
action potential with repetitive nerve stimulation), and a good treatment response to 
acetylcholinesterase (AChE) inhibitors. Genetic evaluation of these families revealed 
pedigrees typical of an autosomal recessive trait but the underlying genetic defect had 
not yet been identified. We localised and refined the genetic interval on chromosome 2 
by homozygosity mapping, identified mutations in the gene encoding glutamine-
fructose-6-phosphate transaminase 1 (GFPT1) as a so-far unrecognized cause of 
CMS and recapitulated human pathology in zebrafish morphants. GFPT1 catalyzes the 
transfer of an amino group from glutamine onto fructose-6-phosphate, yielding 
glucosamine-6-phosphate (GlcN-6-P) and glutamate. This transamidase reaction has 
been identified as the first and rate-limiting step of the hexosamine biosynthesis 
pathway, which is the obligatory source of essential amino sugars for the synthesis of 
glycoproteins, -lipids, and proteoglycans (Figure S1) 7. As many key NMJ proteins are 
glycosylated 8 our data will pave the way for new studies on the functional integrity of 
the neuromuscular synapse. 
Materials and Methods
Patients
Pedigrees and countries of origin of 16 CMS families are shown in Figure S2 and a 
synopsis of clinical findings is shown in Figure 1. Five families, LGM3, LGM4, 
LGM13, LGM15 and LGM16, have been published earlier 9,10. Venous blood samples 
were obtained from the patients as well as from their unaffected parents and siblings. 
Genomic DNA was isolated using the Wizard Genomic DNA Purification Kit 
6(Promega, Mannheim, Germany) according to the manufacturer’s recommendations. 
All genes that are known to cause CMS when mutated (CHAT [MIM 118490], 
CHRNA1 [MIM 100690], CHRNB1 [MIM 100710], CHRND [MIM 100720], CHRNE
[MIM 100725], COLQ [MIM 603033], DOK7 [MIM 610285], RAPSN [MIM 601592], 
MUSK [MIM 601296], SCN4A [MIM 603967], LAMB2 [MIM 150325] and AGRN [MIM 
103320]) and two functional candidate genes (CNTN1 [MIM 600016] and AChE [MIM 
100740]) were excluded by direct sequencing or by haplotype analysis 11. All studies 
were carried out with informed consent of the probands or their legal guardians and 
were approved by institutional ethics review boards in Munich and Newcastle. 
Reagents
If not stated otherwise, all chemicals were obtained from Sigma-Aldrich (Munich, 
Germany). Sequences of oligonucleotide primers are available upon request. 
Linkage analysis
In order to identify the disease locus, we performed homozygosity mapping 12 by 
genome-wide genotyping of single nucleotide polymorphisms (SNP) for family LGM3 
using the Illumina 300K chip (Illumina, San Diego, CA). Multipoint linkage analysis 
was performed with MERLIN 13 assuming autosomal recessive inheritance, a 
frequency of the deleterious allele of 0.001, and complete penetrance. For targeted 
linkage and homozygosity analysis of chromosome 2p12-p15, DNA samples from 
families LGM1, LGM2, LGM5, LGM6, LGM7, LGM8, LGM10, LGM11 and LGM12 
were analysed with short tandem repeat (STR) markers. Twenty-three markers were 
retrieved from the NCBI UniSTS database, and four new polymorphisms were 
identified by using the Repeat-Masker program. PCR primers for new STRs were 
designed by the Primer3 program. Sense primers were labelled with FAM 
7fluorophores (MWG Biotech, Ebersberg, Germany) for detection on an ABI 377 DNA 
sequencer (Applied Biosystems, Foster City, CA). Multipoint LOD-scores were 
calculated with the GeneHunter v2.1r5 program 14 in the EasyLinkage software 
package 15. The genomic localization of the markers was derived from the Marshfield 
map and the University of California Santa Cruz (UCSC) human genome assembly. 
Candidate gene analysis
For selection of candidate genes in the linkage region on chromosome 2p12-p15, we 
used the February 2009 freeze of the UCSC human genome assembly. Forty-six 
known genes and uncharacterized transcripts were located in the 5.92 Mb interval 
between STR markers D2S296 and D2S2977 (Table S1). We ranked the annotated 
sequences with respect to neuromuscular junction and skeletal muscle biology and 
disease. We used information from public databases and characterized proteins in 
silico by BLAST alignments to protein database entries and comparison of domain 
composition and organization with the SMART algorithm. We also investigated 
positional candidate genes for structural and functional homology with the known 
proteins involved in CMS and related disorders. Sixteen genes were screened for 
mutations (Table S1). Primer pairs for each exon including flanking intron sequences 
were designed from genomic sequence using Primer3 (for GFPT1: genomic DNA 
AC114772.5; mRNA, NM_002056.2 and AF334737.1 [muscle isoform 16]; protein, 
NP_002047.2 and AAK15342.1 [muscle isoform 16]). PCR products were directly 
sequenced using ABI PRISM 3730 DNA Analyzer and BigDye Terminator Cycle 
Sequencing Kit version 1.1 according to the protocols of the manufacturer (Applied 
Biosystems). Sequence variants were identified by visual inspection of 
electropherograms. Control samples were screened by restriction enzyme digestion 
or pyrosequencing. PCR primers for pyrosequencing were designed using Primer 
8SNP Design version 1.01 software (Biotage, Uppsala, Sweden). Pyrosequencing was 
carried out as defined by the supplier on a PSQ HS96A instrument (Biotage). 
Samples were analyzed with the PSQ HS96A version 1.2 software (Biotage). 
Plasmid constructs
Human GFPT1 cDNA was amplified from human skeletal muscle cDNA and inserted 
into the EcoRI and NotI sites of the pCMV-Myc vector (Clontech, Mountain View, CA) 
allowing expression of human GFPT1 with an N-terminal Myc-tag. For enzyme 
activity assays, we cloned the GFPT1 constructs into the pEGFP-N1 plasmid 
(Clonetech) and simultaneously removed the EGFP open reading frame to obtain 
untagged GFPT1. The mutants p.Thr15Ala, p.Asp43Val, p.Arg111Cys, p.Ile121Thr, 
p.Asp348Tyr, p.Arg434His, and p.Met492Thr were generated by site directed 
mutagenesis using mismatch primers 17. Orientation of the inserts and absence of 
PCR-induced mutations were verified by sequencing. 
Cell culture
HEK 293, C2C12 and SW13 cells were cultured in Dulbecco’s Modified Eagle’s 
medium (DMEM) supplemented with 10% fetal calf serum. Primary human myoblasts 
were isolated as previously described 18. Myoblasts from patients with GFPT1
mutations and control myoblasts were obtained from the MRC Centre for 
Neuromuscular Diseases Biobank Newcastle, UK, and the Muscle Tissue Culture 
Collection, Friedrich-Baur-Institute, Munich, Germany, and grown in skeletal muscle 
growth medium (PromoCell, Heidelberg, Germany). For differentiation of myoblasts 
to myotubes, the growth medium was removed at a cell density of around 80% and 
cells were incubated in DMEM supplemented with 2% horse serum for seven days. 
9Transfection of HEK 293, SW13 and C2C12 cells
HEK 293 cells were transfected with 3-6 g of wild type and mutated GFPT1 plasmid 
DNA (with and without N-terminal Myc tag) using Polyplus jetPEI transfection reagent 
(Biomol, Hamburg, Germany) according to the manufacturer’s recommendations. 
Transfection of SW13 cells was carried out using FuGene6 transfection reagent 
(Roche Diagnostics, Mannheim, Germany) and transfection of C2C12 cells was 
performed using Lipofectamine 2000 transfection reagent (Invitrogen, Carlsbad, CA) 
according to the manufacturer’s recommendations. Cells were analysed 48 hours 
after transfection by western blot or immunofluorescence staining. 
Preparation of cell and muscle lysates for protein analysis
Cultured cells were scraped off the plastic dish in PBS containing Complete Protease 
Inhibitor Cocktail Tablets (Roche Diagnostics) and pelleted by centrifugation (14,000 
rpm, 5 min, 4°C). Subsequently, cell pellets were h omogenized in lysis buffer (10 mM 
Tris-HCl, 1% SDS; pH 7.4 or PBS with 1% SDS). Muscle biopsy samples were 
homogenised in PBS containing protease inhibitors using a handheld rotor-stator 
homogenizer (TissueRuptor, Qiagen, Hilden, Germany) and SDS was added to the 
lysis buffer to a final concentration of 1%. Homogenized cell or muscle samples were 
then incubated at 95-100°C for 5 min. Debris was re moved by 5 min centrifugation at 
14,000 rpm and supernatants were used for western blot analysis. 
Western blot analysis
Protein concentrations in the extracts were measured with the BCA protein assay 
(Thermo Scientific, Waltham, MA). Protein samples were separated on NuPage 
Novex 4-12% gradient mini gels (Invitrogen) according to the manufacturer’s 
guidelines. After gel separation, proteins were transferred to a PVDF membrane (GE 
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Healthcare, Buckinghamshire, UK) for 1 h at 350 mA. Membranes were washed in 
TBS-T and blocked for 1 h at room temperature in TBS-T with 5% non-fat milk. 
Primary antibodies were incubated overnight at 4oC. The following antibodies were 
used: rabbit polyclonal anti-GFPT1 (Proteintech Group, Chicago, IL; dilution 1:1,000), 
mouse monoclonal anti-Myc 9E10 (Clontech, dilution 1:100), mouse monoclonal RL2 
antibody to O-linked N-acetylglucosamine (Abcam, Cambridge, MA; dilution 1:1,000), 
mouse monoclonal anti-actin Ab-5 (BD Transduction Laboratories, San Diego, CA; 
dilution 1:5,000) and goat polyclonal anti-actin (Santa Cruz Biotechnology, Santa 
Cruz, CA; dilution 1:200). Membranes were washed three times for 10 min with TBS-
T and incubated with secondary goat anti-mouse IgG antibody conjugated to HRP 
(Invitrogen, dilution 1:5,000), goat anti-rabbit IgG conjugated to HRP (Invitrogen, 
dilution 1:5,000) or donkey anti-goat IgG conjugated to HRP (Jackson 
ImmunoResearch, West Grove, PA; dilution 1:10,000) for 1 h at room temperature. 
Bands were detected using an enhanced chemiluminescence kit (GE Healthcare) 
and quantified with the Image J program. 
125I--bungarotoxin binding
The number of AChRs per motor end plate was estimated using 125I--bungarotoxin 
binding and AChE staining as described previously 19. 
GFPT1 enzyme activity assay
The enzymatic activity of untagged wild type and mutant GFPT1 was measured with 
the glutamate dehydrogenase method 20,21. HEK293 cells transfected with GFPT1 
expression constructs were lysed in GFPT buffer (50 mM KH2PO4, 10 mM EDTA, 5 
mM reduced L-glutathione, 12 mM D-glucose-6-phosphate Na2, 1 mM PMSF; pH 7.6) 
and 100 l aliquots of the lysates were mixed with an equal volume of the reaction 
11
buffer (100 mM KH2PO4, 10 mM D-fructose 6-phosphate, 6.0 mM L-glutamine, 0.3 
mM 3-acetylpyridine adenine dinucleotide, 50 mM KCl, 6 U L-glutamate 
dehydrogenase from bovine liver; pH 7.6) and incubated at 37°C for 45 min. The 
change in absorbance was monitored at 370 nm using a Spectra Max 250 microplate 
reader (Molecular Devices, Sunnyvale, CA). The enzymatic activity of each mutant 
was normalized to GFPT1 expression levels determined by western blot analysis of 
cell lysates used for enzyme activity measurements. All transfections and 
measurements were done in triplicates. 
Zebrafish husbandry and observation
We used the wild-type strain *AB (Zebrafish International Resource Centre, Eugene, 
OR). Zebrafish embryos were raised and staged according to standard procedures 
22,23. Video recordings of embryos and larvae and light microscopy images were 
taken using a Leica dissection stereomicroscope equipped with a Moticam 1000 
camera (Leica, Wetzlar, Germany). Touch-evoked swimming response was elicited 
by touching the head or the tail of the embryos with a pipette tip. 
Antisense morpholino oligonucleotide knockdown
Antisense morpholino oligonucleotides (MOs) were purchased from Gene Tools 
(Pilomath, OR). The MOs were designed using the mRNA sequence of the zebrafish 
GFPT1 orthologue gfpt1 and genomic sequences available from public databases 
(GeneID: 567861, accession number: NM_001034981) and the corresponding 
genomic DNA sequence obtained from the zebrafish chromosome 8 assembly. We 
established two MOs to target gfpt1, one translation blocking MO binding to the 
region around the start codon (MO1: 5’-TCAGATACGCAAATATGCCACACAT-3’) 
and one splice blocking MO directed against the splice donor site of intron 5 (MO2: 
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5’-TGCTGGAATGTGTTACTTGCCAGAA-3’). MO2 is expected to interfere with the 
splicing process and lead to a disruption of the protein open reading frame and 
premature translation stop. The Gene Tools “standard control” MO (5’-
CCTCTTACCTCAGTTACAATTTATA-3’) targeting a human -hemoglobin gene was 
used as a negative control for the effects of MO injection. Embryos were injected with 
5-8 ng gfpt1 translation blocking MO1, 2-10 ng of gfpt1 splice blocking MO2 or 15-20 
ng of control MO following standard procedures 22,23. Three independent MO injection 
experiments were performed for each MO and at least 500 injected embryos were 
evaluated in total for each MO. 
RNA isolation and RT-PCR
RNA from zebrafish embryos and human cultured myoblasts, myotubes or muscle 
biopsies was isolated with Trizol reagent (Invitrogen) following the manufacturer’s 
instructions. Reverse transcription was performed with 1 or 2 g total RNA as 
template using the Superscript III First-Strand Synthesis System (Invitrogen). 
Regions of interest in the GFPT1 and gfpt1 cDNA were amplified with suitable primer 
sets. For segregation analysis in families, PCR products from patients’ cDNA 
containing GFPT1 mutations were subcloned into the pGEM-T Easy vector 
(Promega) and individual clones were isolated and sequenced. 
Immunofluorescence stainings
For immunofluorescence analysis, cells were grown on glass coverslips and 
transfected as described above. Forty-eight hours after transfection, coverslips were 
washed in PBS, fixed in 3.7% formaldehyde in 1x CSK buffer (100 mM NaCl, 300 mM 
sucrose, 3 mM MgCl2, 1 mM EGTA, 10 mM PIPES; pH 6.8) for 10 min at room 
temperature, and permeabilized with 0.1% Triton X-100 in 1x CSK buffer for 15 min. 
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After three washes in PBS, nonspecific binding sites were blocked with PBS 
containing 5% horse serum for 1 h, followed by overnight incubation at 4°C with a 
mouse monoclonal anti-Myc 9E10 antibody (Clontech, dilution 1:100) in PBS with 5% 
horse serum. After three washes in PBS, cells were incubated with the secondary 
antibody, goat anti-mouse IgG conjugated to Alexa Fluor 488 (Invitrogen, dilution 
1:500), for 1 h at room temperature. Nuclei were visualized using bisbenzimide H 
33258 (40 µg/ml). Digital images were captured using a Zeiss Axiovert 200 M 
fluorescence microscope and a Zeiss AxioCam HR photo camera (Zeiss, 
Oberkochen, Germany). Whole-mount immunofluorescence staining and imaging of 
zebrafish embryos was done as previously described 24. In brief, NMJ were visualised 
with Alexa Fluor 594 conjugated α-bungarotoxin (Invitrogen, 1 µg/ml) and a mouse 
monoclonal anti-SV2 (synaptic vesicle protein 2) antibody (Developmental Studies 
Hybridoma Bank, Iowa City, IA; dilution 1:200). Slow-twitch muscle fibers were 
visualized with a mouse monoclonal anti-F59 (slow muscle myosin heavy chain, slow 
MyHC) antibody (Developmental Studies Hybridoma Bank, dilution 1:50). 
Statistical analysis
The data show the mean ± SD. Statistical significance was determined using a two-
tailed Student’s t test. Significance was set at P < 0.05 (one asterisk), P < 0.01 (two 
asterisks), or P < 0.001 (three asterisks). 
Results
We had access to eleven so far unreported and two previously reported families with 
limb-girdle CMS with tubular aggregates of various ethnic origins (Figure S2). Direct 
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sequencing or haplotype analysis excluded all known genes and loci previously 
known to be involved in CMS 3. Consanguinity in a Libyan multiplex family with five 
affected children (family LGM3) presented the possibility of locating the disease locus 
by homozygosity mapping 12. Genome-wide genotyping with approximately 300,000 
SNP markers revealed a single hit on chromosome 2p12-p15 with a maximum LOD 
score (logarithm of the odds ratio for linkage) of 3.24 (Figure 1), indicating linkage to 
this locus. Localization of so-far unknown CMS mutations on chromosome 2p was 
further supported by the results of STR marker analysis in additional families suitable 
for homozygosity mapping or linkage analysis (LGM1, LGM2, LGM5, LGM6, LGM7, 
LGM8, LGM10, LGM11, LGM12; Figure S2). Although these pedigrees were too 
small to give significant LOD scores, reconstruction of haplotypes was in full 
agreement with linkage to this locus. We systematically exploited the genotyping data 
to detect potential recombination events. Under the assumption of genetic 
homogeneity, historic recombination events suggested from regions of homozygosity 
in families LGM10 and LGM11 narrowed the critical genetic interval to a region of 
interest of 5.92 Mb (Figure S3). 
We evaluated and ranked the 46 genes in this region (Table S1) on the basis of 
expression pattern and function, and sequenced the entire coding region and exon-
intron boundaries of 16 genes in the index cases from the three families that 
produced the highest LOD scores (LGM1, LGM3 and LGM10). We identified different 
homozygous missense mutations in the gene encoding glutamine-fructose-6-
phosphate transaminase 1 (GFPT1) in these three families (Figure 2) and no 
disease-related changes in any of the other sequenced genes. We obtained further 
evidence for a causative role of GFPT1 mutations when extending GFPT1 mutation 
screening to the remaining 13 families, yielding biallelic mutations in all pedigrees 
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except for families LGM4, LGM15 and LGM16 (Figure S4). We identified a total of 18 
different GFPT1 mutations consisting of 13 missense mutations, three frameshift 
mutations, one nonsense mutation and one variant in the 3’-UTR (Figure 2, Table 1). 
When DNA from family members was available, we observed that the disease 
cosegregated with recessive inheritance of the GFPT1 mutations. The parents 
carried mutations in the heterozygous state, and unaffected siblings carried either 
one heterozygous mutation or were homozygous for the wild type alleles. When DNA 
from family members was not available (families LGM9 and LGM13), subcloning and 
sequencing of amplicons from cDNA derived from muscle biopsies demonstrated that 
the mutations were on separate alleles. We observed that some GFPT1 missense 
mutations caused rather mild amino acid changes or affected residues that are not 
strictly conserved in orthologues (Table 1, Figure S5). Nevertheless, analysis of 
extended numbers of healthy control individuals, adjusted to the type of mutation (at 
least 103 for each truncating and 221 for each missense mutation; 635 for the 3’-
UTR variant), did not yield any of the identified genotypes (Table 1).  
We noted that the crystal structures of the E. coli orthologue for GFPT1 (GlmS) and 
of the isomerase domain of human GFPT1 had been solved (Protein Data Bank 
[PDB] accession numbers 2J6H and 2ZJ3) 25,26. Using this data as the basis of a 
structural model for human GFPT1, the c.1154G>A (p.Arg385His) mutation would be 
predicted to impair GFPT1 function, since the arginine residue at position 385 in 
human GFPT1 corresponds to E. coli GFPT1 arginine 312 which contributes to the 
GFPT1 dimer interface. Other GFPT1 missense mutations do not affect amino acid 
residues required for oligomerisation or involved in the catalytic mechanism. 
Consistent with this observation heterologous protein expression of the GFPT1 
mutants p.Thr15Ala, p.Asp43Val and p.Asp348Tyr had only small effects on 
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enzymatic activity and of the mutants p.Arg111Cys and p.Arg434His no effect at all 
(Figure S6). We also did not observe any major effect of the GFPT1 mutations on 
subcellular localization of the protein in transfected cells (Figure S6). By contrast, we 
found substantially reduced GFPT1 levels in muscle biopsies (Figure 2) and cultured 
primary myoblasts and myotubes obtained from GFPT1 patients (Figure S6). 
Reduced amounts of GFPT1 were also seen in patients with the 3’-UTR mutation 
c.*22C>A (LGM5.5, LGM9.3). 
We also set up experiments to follow potential indirect or direct functional 
consequences of GFPT1 mutations. Radiometric assays showed a strongly reduced 
number of AchR available for 125I--bungarotoxin binding at motor end-plates of 
GFPT1 patient LGM8.3 (to around 25% of normal). The end product of the 
hexosamine pathway, uridine diphospho-N-acetylglucosamine (UDP-GlcNAc), is 
involved in multiple glycosylation processes 7 including the dynamic modification of 
serine or threonine residues of intracellular proteins (O-GlcNacylation) 27 (Figure S1). 
We therefore immunoblotted muscle samples of GFPT1 patients and controls with 
the RL2 antibody, which selectively detects O-GlcNAc residues on numerous 
proteins 28. As expected, the antibody recognized several bands whose intensities 
were markedly decreased in muscles from GFPT1 patients (Figure 2). 
In a final series of experiments, we used zebrafish as an animal model. GFPT1 is 
conserved in zebrafish, with high expression levels during early somite development 
(data not shown). We knocked down the expression of the zebrafish GFPT1 
orthologue gfpt1 by injection of antisense morpholino oligonucleotides (MOs), a 
translation-blocking MO targeting the region surrounding the start codon (MO1) and a 
splice-blocking MO targeting the splice donor site of intron 5 (MO2). Both MOs 
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induced a clear reduction of gfpt1 levels at 48 hours post fertilization (hpf) (Figure 
S7). Knockdown of neuromuscular junction proteins usually affects motility and 
swimming behaviour of injected embryos. Indeed, MO-injected embryos displayed 
altered tail morphology (curled tails and shortened tails, Figure 3), and swimming and 
touch-evoked escape response at 48 hpf were severely impaired (Video S1). 
Histologically, we observed abnormal muscle morphology and delayed NMJ 
development. Somites had lost their regular chevron-shape with rounding of 
myosepta to a C-shape instead of the V-shape in control embryos. Staining for slow-
twitch muscle fibers revealed morphological abnormalities ranging from wavy fibers 
to severely damaged fibers that were detached from the vertical myoseptum (Figure 
3). NMJ development progressed normally up to 24 hpf, but from 24 hpf onwards, 
NMJ development was delayed. Motor neuron axons had completely or partially lost 
their ability to project branches into laterally located muscle fibers and to form 
synapses with them (Figure 3). Both MOs resulted in strikingly similar phenotypes 
while embryos injected with a standard control MO were indistinguishable from non-
injected embryos (data not shown). 
Discussion 
In this study we provide twofold genetic evidence that GFPT1, the key enzyme of the 
hexosamine pathway yielding essential amino sugars for carbohydrate modifications, 
is required for critical events in neuromuscular transmission. Specifically, we 
localized and refined the genetic interval for a so far genetically undetermined 
autosomal recessive CMS on chromosome 2 and identified GFPT1 mutations as the 
molecular defect. This finding was recapitulated by a neuromuscular morphant 
18
phenotype observed in zebrafish embryos lacking GFPT1. We found 18 different 
homozygous and compound heterozygous GFPT1 mutations in 13 unrelated 
families, and GFPT1 mutations occurred in CMS cohorts of various ethnic origins. 
Although failure to detect mutations in three additional cases is probably related to 
so-far unexplored mutation mechanisms or involvement of additional unknown 
genes, our data indicates that GFPT1 mutations represent the major cause for limb-
girdle CMS with good treatment response to AChE inhibitors or tubular aggregates in 
muscle biopsies. With respect to genetic diagnosis and counselling, limb-girdle CMS 
patients with effective response to AChE inhibitors or tubular aggregates in muscle 
biopsies should undergo GFPT1 sequencing while all other limb-girdle CMS patients 
should be screened for DOK7 mutations first and – if negative – for GFPT1
mutations. 
In metazoa, there are two GFPT genes, GFPT1 and GFPT2, encoding isozymes with 
different tissue distributions 29. GFPTs are homodimeric, cytoplasmic enzymes that 
transfer an amino group from glutamine onto fructose-6-phosphate, yielding 
glucosamine-6-phosphate (GlcN-6-P) and glutamate. This reaction is the first and 
rate-limiting step of the hexosamine biosynthesis pathway (Figure S1), which is the 
obligatory source of essential building blocks for the glycosylation of proteins and 
lipids 7. GFPT1 is the only or predominant isoform in kidney, pancreas and liver. 
Since glycosylation is essential for cell survival it might be expected that GFPT1
mutations create hypomorphic alleles. Indeed none of our patients carries two null 
mutations in the constitutive exons of the GFPT1 gene. The homozygous p.Trp240X 
mutation (family LGM2) is predicted to lead to decreased GFPT1 levels only in heart 
and skeletal muscle as it occurs in an alternative 18-amino-acid exon, exclusively 
incorporated in the predominant GFPT1 species in striated muscle 16. The expected 
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residual function of GFPT1 mutants is also consistent with our finding that some 
GFPT1 missense mutations result in amino acids with similar physicochemical 
properties or affect residues that are not strictly conserved in orthologues (Figure 
S5). 
With the notable exception of p.Arg385His, which potentially affects GFPT1 
dimerisation, in silico structural modelling and heterologous expression studies did 
not reveal definite pathophysiological effects of GFPT1 mutants. However, protein 
expression data in patients’ muscle cells and biopsy specimens suggest that GFPT1
mutations may lead to substantially reduced GFPT1 levels. The mechanism by which 
the mutants inhibit protein expression remains to be determined but may involve 
reduced levels of GFPT1 mRNA, increased GFPT1 turn-over, or interference with 
protein translation. Notably, the 3’-UTR mutation c.*22C>A (patients LGM5.5, 
LGM9.3) was also associated with reduced amounts of GFPT1. For this particular 
mutation the combination of an observed decrease in protein levels, its presence in 
three unrelated families, its absence in a large number of control chromosomes, and 
compound heterozygosity with a truncating mutation in one family strongly suggests 
that c.*22C>A is a disease-causing variant. Nevertheless, the pathogenic mechanism 
at the molecular level of c.*22C>A is not yet clear. Analysis of the GFPT1 skeletal 
muscle mRNA by RT-PCR in two patients excluded effects on splicing and showed 
similar levels of wild-type and mutated position c.*22 mRNA expression (Figure S6). 
It is possible that this mutation, like many 3’-UTR mutations in other genes, affects 
translational efficiency 30. 
Other CMS related genes known to date encode structural components of the 
neuromuscular junction while GFPT1 is believed to play a more general role in the 
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cell. The product of the transamidase reaction catalyzed by GFPT1, GlcN-6-P, is 
used in the hexosamine pathway to synthesize uridine diphospho-N-
acetylglucosamine (UDP-GlcNAc) that serves as common precursor for all amino 
sugars used for the synthesis of glycoproteins, -lipids, and proteoglycans (Figure S1) 
7. Many key NMJ proteins are glycosylated 8 including MuSK, AChR subunits, agrin, 
dystroglycan, and integrins. Interestingly, a missense mutation removing one of the 
N-glycosylation sites of the epsilon subunit of the AChR causes CMS 31. Moreover, 
treatment with tunicamycin (an inhibitor of protein glycosylation) and in vitro
mutations of AChR subunits that prevent glycosylation severely reduce cell surface 
expression of AChR, either through a decrease of metabolic stability or through a 
failure in efficient assembly of the pentameric AChR 32. UDP-GlcNAc is also 
extensively involved in intracellular signaling in a wide range of species. N-
acetylglucosamine is reversibly attached to serine or threonine residues of 
cytoplasmic and nuclear proteins, similar to phosphorylation (O-GlcNAcylation) 27. 
Reduced endplate AChR numbers and decreased protein O-GlcNAcylation in 
patients’ muscles observed in our study may provide a first glimpse at the molecular 
and cellular consequences of GFPT1 mutations. Lectin stainings, digestions with 
glycosidases, antibodies to carbohydrate-linked proteins or mass spectrometry-
based techniques are likely to demonstrate specific changes in protein glycosylation. 
Identification of such changes may also help to clarify why, while universally required, 
the functions of the NMJ is especially vulnerable to alterations of the hexosamine 
pathway. 
In order to obtain further proof that a reduction of GFPT1 levels leads to NMJ or 
muscle dysfunction we utilized zebrafish as an animal model. Although overall the 
muscle structure of zebrafish differs from mammalian muscles 33, NMJ formation 
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occurs in a similar stepwise sequence, and zebrafish mutants and morphants have 
previously proved a good model system for studies of myasthenic syndromes and 
NMJ function 24,34-36. Morpholino-mediated knockdown of gfpt1 in zebrafish embryos 
induced a neuromuscular phenotype and resulted in altered muscle histology and 
delayed NMJ maturation. This data provides another level of genetic evidence and 
independently confirms that GFPT1 is required for normal NMJ formation. 
Although the precise pathogenic mechanisms involved remain to be determined, our 
work highlights amino sugar metabolism as a novel pathophysiological mechanism 
that can underlie NMJ disorders and will open a new area to explore for treatment 
options. Because the vertebrate NMJ is a classic model synapse due to its 
comparatively large size and easy accessibility 37, further investigation of the role of 
GFPT1 for NMJ function is likely to also contribute to our understanding of synapse 
development and organization in general. Although there are no clear-cut 
associations in our patients we note that GFPT1 and the hexosamine pathways have 
been implicated in signalling pathways that may become deregulated in diseases of 
the immune system, diabetes mellitus, cancer, cardiovascular disease, and 
neurodegenerative diseases 38,39. Our findings give additional impetus for 
investigating the role of GFPT1 in human health and disease. 
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Supplemental Data
Supplemental Data include seven figures, one table and one video. 
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Figure Legends
Figure 1. Phenotype of CMS patients in this study and linkage to chromosome 2p12-
p15. (A) Relative frequency of signs and symptoms in our patient cohort (n = 23). 
RNS, repetitive nerve stimulation; EMG, electromyography; CK, creatine kinase. (B) 
Patient LGM10.4: Proximal muscle weakness and hyperlordotic posture at prolonged 
arm elevation. (C) Patient LGM12.3: Scapular winging. (D) Genome wide linkage 
analysis of family LGM3. Analysis was performed using MERLIN with the assumption 
of autosomal-recessive inheritance with complete penetrance and a disease allele 
frequency of 0.001. 
Figure 2. Identification of GFPT1 mutations. (A) GFPT1 mutations detected in 
families used for candidate gene sequencing. Chromatogram pairs of an unaffected 
individual and an affected patient are shown. The asterisks indicate the position of 
the mutations. Base and amino acid changes with the corresponding position in the 
nucleotide and protein sequence are given above chromatograms displaying GFPT1 
mutations. The numbering of nucleotides and amino acids follows NM_002056.2 and 
NP_002047.2 which represent the short, ubiquitous isoform of GFPT1. Nucleotide 
numbering uses the A of the ATG translation initiation start site as nucleotide +1. (B) 
Domain structure of GFPT1 and position of mutations. GFPT1 contains a 
glutaminase and two sugar isomerase (SIS) domains. The site of insertion of 18 
additional amino acids (hashed box) encoded by a muscle specific exon 16 is 
indicated. Missense mutations are in black, truncating mutations are in red. The 3’-
UTR mutation is not shown. The numbering of nucleotides and amino acids is as in 
(A), except for the c.719G>A (p.Trp240X) mutation in the muscle specific exon, for 
which we used numbering of the longer GFPT1-L sequence 16. aa, amino acid. (C) 
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Western blot of GFPT1 and O-GlcNAcylation in muscle biopsies of GFPT1 patients. 
Muscle lysates of patients LGM9.3, LGM5.5, LGM10.4 and LGM11.3 and two healthy 
control individuals were immunoblotted with an anti-GFPT1 antibody (upper panel), 
the RL2 antibody (detects single N-acetylglucosamine at serine or threonine 
residues, middle panel) and an anti-actin antibody (as loading control, bottom panel). 
GFPT1 band intensities were normalized to actin bands in the same lane. Total 
GFPT1 levels (GFPT1-L and the shorter ubiquitous isoform) in patients’ muscles 
were reduced to 29%, 8%, 9% and 26% of the level in control muscle 1. The levels of 
O-linked N-acetylglucosamine on proteins were also markedly decreased in patients’ 
muscles. The membrane was first decorated with the anti-GFPT1 antibody and later 
reprobed with the RL2 and anti-actin antibodies. 
Figure 3. Gpft1 knockdown in zebrafish embryos. (A to D) Live embryos at 24 and 
48 hpf injected with the translation-blocking gfpt1 antisense morpholino oligo MO1 (A
and B) and non-injected controls (C and D). Note increased tail curvature in gfpt1 
morphants. (E to P) Whole-mount immunostainings of zebrafish embryos. Slow-
twitch muscle fiber structure in 48 hpf gfpt1-MO1 injected morphants (E to G) and 
non-injected controls (H to J). Embryos were stained for AChR (α−bungarotoxin) and 
slow-twitch muscle fibers (anti-slow muscle myosin heavy chain (slow MyHC), F59 
antibody). Gfpt1 morphants show severe muscle fiber defects with detachment of 
fibers from the vertical myoseptum. Somites have lost their chevron shape. Scale 
bars: 50 m. (K to P) Neuromuscular junctions in 48 hpf gfpt1 morphants (K to M) 
and non-injected controls (N to P). Embryos were stained for AChR (α−bungarotoxin) 
and presynaptic nerve endings (anti-SV2 antibody). In controls, motor axons have 
branched out into all parts of the somite where they form contacts with AChR 
clusters. In gfpt1-MO1 injected embryos AChR clusters are predominantly located 
33
along the medial surface of the somite, and motor axons form fewer branches than in 
controls. Scale bars: 50 m. 
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Figure S1. Hexosamine biosynthesis pathway. GFPT is the rate limiting enzyme in 
this pathway. The end product UDP-N-acetylglucosamine serves as precursor for 
essential amino sugars used for the synthesis of glycoproteins, -lipids, and 
proteoglycans, and for the dynamic posttranslational protein modification O-linked N-
acetylglucosamine on serine or threonine residues. CoA, coenzyme A; P, phosphate. 
2
Figure S2. Pedigrees of the CMS families included in this study. Squares represent 
males, circles represent females, and diamonds were used when it was not important 
to specify the gender or if the information was unknown. A double line between 
parents indicates consanguineous marriages. Filled symbols represent affected 
individuals. Red bars over the pedigree symbols indicate from which individuals 
genomic DNA was obtained and used for genotyping. Clinical data were available for 
patients marked with asterisks. Families LGM3, LGM4, LGM13, LGM15 and LGM16 
have been reported previously 9,10.
3
Figure S3. Refined recombinational map of the critical interval. The specific 
recombination events between the locus and polymorphic 2p12-p15 DNA markers 
are shown in individuals from nine families. Polymorphic markers used in this study 
are given in pter-cen orientation. The physical map positions are according to the 
UCSC February 2009 freeze. “D2S” locus numbers indicate STR markers obtained 
from public databases, “AC” numbers indicate newly established STR markers and 
“rs” numbers indicate SNP markers extracted from the genome-wide linkage data for 
family LGM3. Grey circles indicate the disease-associated haplotype, black circles 
indicate homozygosity for the disease-associated haplotype and white circles indicate 
the non-disease-associated haplotype. Bars indicate non-informative markers (no 
symbol: untyped markers). The recombination events suggested from regions of 
homozygosity in patients of families LGM10 and LGM11 support a 5.92-Mb region of 
interest flanked by markers D2S296 and D2S2977 (arrowheads). 
4
Figure S4. Identification of GFPT1 mutations. Chromatogram pairs are shown, one 
of an unaffected individual and the other of an affected patient. The asterisks indicate 
the position of the homozygous and heterozygous mutations. Base and amino acid 
changes with the corresponding positions in the nucleotide and protein sequences 
are given above chromatograms displaying GFPT1 mutations. The crosshatch 
symbol indicates reverse strand chromatograms. For numbering of nucleotides and 
amino acids please refer to the legend of Figure 2. 
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Figure S5. Cross-species conservation of mutated GFPT1 amino acid residues. 
Missense mutations identified in CMS patients are indicated above the alignments.
The corresponding regions of eleven different organisms were aligned by using the 
ClustalW algorithm. Note that not all mutations target highly conserved residues. In 
the case of the p.Met491Thr mutation there is even a threonine already present at 
this position in the C. elegans sequence. On the other hand, the micro environment 
of this residue which points into the inner part of the molecule (PDB accession 
number 2V4M for human GFPT1 isomerase domain) is supposed to be different and, 
thus, may cause a disadvantage of the hydrophilic threonine residue over the 
hydrophobic methionine in the human GFPT1 structure. Similarly, the GFPT1 
mutation p.Arg512Trp is in a region which is conserved in the closely related 
mammals (e.g., pig and mouse). In other organisms, this position is exchanged by 
residues smaller than arginine, suggesting that the bulky tryptophane in this position 
may produce sterical hindrance.
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Figure S6. Characterization of mutant GFPT1 species. (A) Analysis of the enzymatic 
activity of GFPT1 mutants. HEK293 cells were transfected with either wild type or 
mutant GFPT1 constructs. GFPT1 enzyme activity was measured in cell lysates with 
the glutamate dehydrogenase method 48 h after transfection. (Continued on page 8.) 
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Figure S6. (Continued from previous page.) The enzymatic activity of each mutant 
was normalized to GFPT1 protein amounts determined by western blot analysis of 
cell lysates used for activity measurements. Three independent transfection 
experiments were performed for each mutant and lysates were measured in 
triplicates. Error bars indicate + SD; significant differences from wild type **P < 0.01; 
***P < 0.001. n.s., not significant. (B) Subcellular localization of GFPT1 mutants. 
SW13 cells were transfected with either wild type or mutant Myc-tagged GFPT1 
constructs. Cells were stained with a mouse monoclonal antibody that recognizes the 
Myc-tag, followed by a secondary antibody conjugated to a green fluorescent dye 
(Alexa Fluor 488). All mutants show a cytoplasmic staining pattern similar to wild type 
GFPT1. Similar results were obtained in C2C12 and HEK293 cells (data not shown). 
At high expression levels, some GFPT1 constructs, including wild type, tend to form 
aggregates, which might be non-specific. (C) Western blot analysis of GFPT1 
expression in myoblasts (MB) and differentiated myotubes (MT). Cell lysates of 
cultured myoblasts and differentiated myotubes of patients LGM9.3 and LGM5.5 and 
one healthy control donor were immunoblotted with an anti-GFPT1 antibody (upper 
panel). Expression of the muscle specific longer isoform GFPT1-L can be detected 
only in myotubes, not in myoblasts. The membrane was stripped and reprobed with 
an anti-actin antibody to ensure for equal loading (bottom panel). GFPT1 band 
intensities were normalized to actin bands in the same lane. Comparison of total 
GFPT1 amounts in patients and control (GFPT1-L and the shorter non-muscle 
isoform) showed a reduction of GFPT1 expression to 51% and 22% of the GFPT1 
amount in control myoblasts, and to 40% and 31% of the GFPT1 amount in control 
myotubes. (D) Sequence analysis of genomic DNA and cDNA of patient LGM9.3 for 
the GFPT1 c.*22C>A mutation (asterisks). Sequence analysis of genomic DNA 
shows heterozygosity at position c.*22. Analysis of cDNA shows biallelic expression 
of C and A alleles at position c.*22. Reverse strand chromatograms are shown. 
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Figure S7. Downregulation of gfpt1 levels by injection of antisense morpholino 
oligonucleotides into zebrafish embryos at the one-cell stage. (A) RT-PCR analysis of 
gfpt1 transcripts from embryos injected with the splice-blocking gfpt1 MO2 which 
targets the splice donor site of intron 5. Using primers in exons 3 and 7, RT-PCR 
yielded two additional bands in MO2-injected embryos that were subsequently 
characterized by DNA sequencing. The lower band represents a transcript lacking 
exon 5, whereas the higher band contains an insertion of a partial intron 5 sequence. 
Some wild type transcript is still present. (B) Western blot analysis of gfpt1 levels in 
embryos of different age (12 hpf - 5 dpf) and in 48 hpf embryos injected with either 
the translation-blocking gfpt1 MO1 or the splice-blocking MO2. Gfpt1 levels are high 
at 12 hpf, drop at 24 hpf and increase again later in development. A residual amount 
of gfpt1 can still be detected in injected embryos. Equal protein amounts were loaded 
onto the gel as determined by the BCA protein assay to ensure for equal loading. 
Note that embryos at different stages of development express different levels of actin 
as displayed in the lower panel. 
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Table S1: Positional candidate genes. 
Genomic position Gene name GenBank Strand
Start End
Number of 
exons
Mutation 
analysis 
MEIS1 NM_002398 + 66662531 66799890 13 + 
ETAA1 NM_019002 + 67624441 67637533 6 - 
C1D NM_001190265 - 68269332 68290159 6 - 
WDR92 NM_138458 - 68357280 68384656 8 + 
PNO1 NM_020143 + 68385004 68403089 7 - 
PPP3R1 NM_000945 - 68405988 68479651 6 + 
CNRIP1 NM_001111101 - 68511303 68547183 3 - 
PLEK NM_002664 + 68592321 68624584 9 + 
FBXO48 NM_001024680 - 68689506 68694390 4 - 
APLF NM_173545 + 68694690 68807293 10 - 
PROKR1 NM_138964 + 68872953 68882706 2 + 
ARHGAP25 NM_001007231 + 68961912 69053948 11 + 
BMP10 NM_014482 - 69092612 69098649 2 - 
GKN2 NM_182536 - 69172364 69180102 6 - 
GKN1 NM_019617 + 69201704 69208111 6 - 
ANTXR1 NM_032208 + 69240275 69476457 18 - 
GFPT1 NM_002056 - 69546904 69614382 19 + 
NFU1 NM_015700 - 69623254 69664753 8 + 
AAK1 NM_014911 - 69685126 69870977 22 + 
ANXA4 NM_001153 + 69969126 70053594 13 + 
GMCL1 NM_178439 + 70056817 70106730 14 -
SNRNP27 NM_006857 + 70121089 70132348 6 -
MXD1 NM_002357 + 70142202 70170074 6 +
ASPRV1 NM_152792 - 70187225 70189397 1 -
LOC400960 NR_033872 - 70189395 70314147 11 -
PCBP1 NM_006196 + 70314584 70316332 1 -
C2orf42 NM_017880 - 70377018 70418151 10 -
TIA1 NM_022173 - 70436576 70475779 13 -
PCYOX1 NM_016297 + 70485230 70508316 6 -
SNRPG NM_003096 - 70508509 70520869 4 -
FAM136A NM_032822 - 70523108 70529220 3 -
TGFA NM_003236 - 70674418 70781105 6 +
ADD2 NM_017488 - 70889215 70995375 17 +
FIGLA NM_001004311 - 71004441 71017775 5 -
CLEC4F NM_173535 - 71035778 71047732 7 -
CD207 NM_015717 - 71057343 71062953 6 -
VAX2 NM_012476 + 71127719 71160573 3 -
ATP6V1B1 NM_001692 + 71162997 71192560 14 -
ANKRD53 NM_024933 + 71205574 71212628 7 -
TEX261 NM_144582 - 71213069 71222001 6 -
NAGK NM_017567 + 71295407 71305998 10 +
MCEE NM_032601 - 71336805 71357394 3 -
MPHOSPH10 NM_005791 + 71357443 71377230 11 -
PAIP2B NM_020459 - 71409867 71454233 4 -
ZNF638 NM_014497 + 71558888 71662187 28 +
DYSF NM_001130981 + 71680752 71913892 56 +
+, mutation analysis performed; -, not investigated. 
Video S1. Comparison of motility and touch-evoked swimming response of gfpt1 MO 
injected and non-injected zebrafish embryos at 48 hpf. Non-injected embryos swim 
away quickly when touched with a fine pipette tip, whereas gfpt1 deficient embryos 
hardly move when touched. 
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